FDA Clearance Tracker · P010013-S085
NovaSure Impedance Controlled Endometrial Ablation System
Last checked: Nov 20, 2026Latest source record: Jan 4, 2022 (this decision)Source: openFDAMethods & limitations
Decided
Jan 4, 2022
Approved
Time to decision
92 days
Received Oct 4, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
PMA supplement
Normal 180 Day Track No User Fee
Device class
Class III
The decision
- FDA number
- P010013-S085
- Device name
- NovaSure Impedance Controlled Endometrial Ablation System
- Applicant
- Hologic, Inc.
- Applicant location
- Malborough, MA
- Received
- Oct 4, 2021
- Decided
- Jan 4, 2022
- Decision
- Approved
- Supplement type
- Normal 180 Day Track No User Fee
- Reason for supplement
- Postapproval Study Protocol
- Original approval
- P010013
Device type
- Device type
- Device, thermal ablation, endometrial (MNB)
- Device class
- Class III
- Specialty
- Obstetrics & Gynecology
FDA's approval statement
As written in FDA's record.
Approval for a revision to the NovaSure post approval study protocol, S0112003.
Source documents
Other decisions for Hologic, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- I-View®510(k)
K254090 · Decided Sep 2, 2026 · 257 days after receipt
Device type: Full Field Digital, System, X-Ray, Mammographic (MUE) · Radiology & Imaging
7 more FDA decisions with a free account
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.